Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC Luxeptinib | 1616428-23-9 | 495.43 | 50 MG
Supplier: Medchemexpress LLC HY13953550MG
Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent, and potent pan-FLT3/pan-BTK inhibitor. It has been shown to induce cell cycle arrest, apoptosis, or autophagy in acute myeloid leukemia cells. Luxeptinib also inhibits cell proliferation and suppresses BCR signaling-induced phosphorylation.
- Orally active, reversible, first-in-class, non-covalent, and potent pan-FLT3/pan-BTK inhibitor.
- Induces cell cycle arrest, apoptosis, or autophagy in acute myeloid leukemia cells.
- Inhibits cell proliferation with an IC50 of 32 nM in MEC-1 CLL cells.
- Suppresses BCR signaling-induced phosphorylation of BTK, PLCγ2, AKT, ERK1/2, and S6 ribosomal protein in primary chronic lymphocytic leukemia (CLL) cells.
- Completely inhibits phosphorylation of FLT3 and STAT5 in MV4-11 cells.
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?